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Summary
How the brain performs higher cognitive functions such
as learning and memory is traditionally studied by inves-
tigating how neurons work. However, over the past two
decades, evidence has accumulated which suggests that
components of the extracellular matrix contribute to the
storing of information through learning processes. Thus,
matrix regulation – either changes in the protein compo-
sition of the perineural network surrounding neurons or
cleavage of this network by specific metalloproteases –
could be relevant to the many psychiatric disorders that
are shaped by previous experiences, i.e. by learning and
plasticity. This includes disorders which are a direct con-
sequence of past experiences and ones where previous
experiences constitute a risk factor. Psychotherapy is one
of the first-line treatments for most psychiatric conditions,
and involves learning and plasticity. Here, we review se-
lected publications pertaining to experience dependence
in psychiatric conditions and summarise evidence of roles
for the extracellular matrix in learning and memory. We
then suggest how control of the extracellular matrix could
be leveraged for innovative treatments and, more general-
ly, discuss possible aetiological effects of extracellular ma-
trix alterations in psychiatric disorders.
Keywords: Psychiatry, anxiety disorders, addiction, extra-
cellular matrix, perineuronal nets, synaptic plasticity, circa-
dian rhythms
Introduction
The extracellular matrix (ECM) is the structure that sur-
rounds all cells in the body, including neurons and glia in
the brain. It makes up about 20% of the brain's entire mass
[1]. The ECM is tightly coupled to the cells it surrounds:
its components are produced and secreted by the cells, and
conversely, they impact back on those cells. The ECM
serves various functions across the body: determining me-
chanical tissue properties, guiding cell migration, provid-
ing adhesion loci for individual cells, and enabling inter-
cellular communication [2]. The ECM fills the intercellular
space across the brain and spinal cord, and its composi-
tion is variable [1]. Here, we focus on two specific com-
ponents of the ECM in the brain that are involved in high-
er cognitive functions. Matrix metalloproteinases (MMPs)
are enzymes that sculpt the proteoglycan structures of the
ECM, but they also play a role in the extracellular sig-
nalling pathways involved in the remodelling of excitatory
synapses during learning [3, 4]. Perineuronal nets (PNNs)
are lattice-like protein structures that scaffold specific neu-
rons, mostly inhibitory interneurons [3]. Their integrity ap-
pears to be important for synaptic plasticity and learning
[5]. Both these ECM components could, in different parts
of neural microcircuits, be key players in the development
of disorders based on memory and learning (such as anx-
iety disorders, post-traumatic stress disorder or addiction),
as well as during the plasticity-dependent psychotherapeu-
tic modulation of mental disorders.
This review has three aims. To provide a cognitive back-
ground, we first discuss the psychiatric conditions for
which synaptic plasticity may be relevant, important re-
search paradigms used to investigate the synaptic basis of
memory, and potential strategies for memory modification.
We then review the molecular evidence that ECM com-
ponents are involved in the formation and maintenance of
memory, and how this could be leveraged for treatment.
Finally, we summarise initial clinical evidence that ECM
pathology, such as PNN dysfunction, may be causally in-
volved in some psychiatric conditions.
Experience dependence in psychiatric disor-
ders
A range of psychiatric disorders are caused or shaped by
previous adverse experiences or potentially traumatic
stressors. Prime exemplars are post-traumatic stress disor-
der (PTSD) and acute stress disorder, which are by defin-
ition responses to a specific event. Memories of this event
are key to the development of symptoms and thus synaptic
changes [6]. Another obvious example is addiction, which
requires exposure to a drug. It appears plausible that some
form of synaptic plasticity plays a role in the development
of addiction [7]. Other disorders may develop with or with-
out the presence of a particular, defined experience, but if
present this experience can contribute to the development,
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maintenance or exacerbation of symptoms. For example,
early adverse experience is considered a risk factor for a
broad range of psychiatric conditions [8]. A meta-analysis
of prospective studies showed that childhood maltreatment
increases the risk of later depression by a factor of 2, and
of anxiety disorders by a factor of 2.8 [9]. Another type
of experience is parental loss due to death or separation,
and a retrospective study showed that parental loss before
the age of 9 years is about 10 times more frequent in indi-
viduals who later develop unipolar depression than in the
healthy population [10]. Even disorders with a strong ge-
netic determination, such as schizophrenic psychosis, ap-
pear to be exacerbated or worsened by an early adverse ex-
perience [11].
These striking correlations motivate us to question how
synaptic plasticity mechanisms contribute to the develop-
ment and maintenance of psychiatric disorders. Because
not all individuals exposed to a particular experience (such
as trauma) develop a condition (such as PTSD), pre-expe-
rience synaptic pathology may be causally involved. Fur-
thermore, when particular memories are important for the
maintenance of a disorder, targeting synaptic plasticity
mechanisms may provide a way to treat the condition,
since synaptic weights form the biological basis of memo-
ry [12].
Moreover, synaptic plasticity changes are the biological
basis for psychotherapy, a standard first-line or adjunct
treatment for most psychiatric conditions. Some forms of
psychotherapy (for example, cognitive behavioural thera-
py) specifically build on learning principles, modulating
specific emotional memories or dysfunctional beliefs and
cognitions. Learning processes are known to involve
synaptic plasticity [6]. Other therapies are not founded pri-
marily on such principles, but nevertheless modify subjec-
tive experience and behaviour, which are likely to rely on
learning and plasticity in some form.
Therefore, synaptic plasticity provides a way to induce
change, independent of the aetiology of a psychiatric con-
dition. This is not unlike the plastic changes generated by
physiotherapy or speech therapy after a stroke or brain in-
jury, whose success does not depend on the aetiology of the
lesion. Although the precise microscopic and macroscop-
ic mechanisms underlying psychotherapy remain elusive,
attempts have been made to integrate psychotherapy with
pharmacological interventions aimed at plasticity facilita-
tion [13]. We will review some of these after presenting the
laboratory models used to study the synaptic basis of mem-
ory.
Pavlovian fear conditioning as a model of ad-
verse experience
Memory is the storage of information acquired during an
individual's lifetime [14]. Many different forms of memory
exist in mammals, including declarative memory, or ex-
plicit memory, referring to the conscious, intentional rec-
ollection of factual information and previous experiences,
thus corresponding to the colloquial meaning of the word
"memory". There are also other ways in which information
is retained, including partly or entirely non-conscious
memories (e.g. motor memory). At least some of them
involve plasticity in macroscopically distinct brain areas
[15]. Some of the experience-dependent mechanisms dis-
cussed in the context of psychiatric disorders involve
memories for reward prediction or memories for particular
behavioural patterns. However, adverse experience is ar-
guably the most widely relevant type of experience in the
causation and development of psychiatric conditions. This
is why laboratory research has largely focused on aversive
memories. A memory test used particularly widely in hu-
mans and non-humans is Pavlovian fear conditioning, also
termed threat conditioning [16]. This paradigm, in which
an individual is passively exposed to predictors of an aver-
sive event, is experimentally simple and serves as a ba-
sic mechanistic model of psychiatric conditions such as
post-traumatic stress disorder [17]. In this paradigm an ini-
tially neutral cue (e.g. a coloured light, termed the con-
ditioned stimulus, CS+) is contingently coupled with an
aversive event (e.g. an electric shock, termed the uncondi-
tioned stimulus, US). Many animal species, including hu-
mans, show responses to the CS+ after a few pairings, for
example freezing behaviour in rodent species, or bradycar-
dia in many mammals including humans [18]. This type
of memory is usually retained for a prolonged period of
time. In animals, it can be retained for a lifetime [19]. Cru-
cially, and with relevance to psychotherapy, such memo-
ries may persist even if the animal (or human) is exposed to
contrary experiences. In an experimental paradigm termed
extinction learning, the individual is exposed to the same
CS+, but this time no longer followed by the US, and
over time they will reduce their conditioned response to
the CS+. Crucially, the initial fear memory remains intact
during extinction, but the organism acquires an additional,
inhibitory memory about the safety of the CS+ [20]. The
persistence of the initial fear memory can be probed in
tests in which the context changes from the extinction con-
text. For example, conditioned responses re-emerge after a
passage of time (spontaneous recovery, change of tempo-
ral context), after the delivery of an unsignalled US (rein-
statement, change of threat context), or when exposed to
a novel environment (renewal, change of spatial context)
[21]. This may resemble the clinical phenomenon of re-
lapse in the years after, for example, cognitive-behavioural
psychotherapy for phobia [21].
Learning theory regards extinction as a form of meta-learn-
ing. Memories do not get “erased” and the individual con-
tinues to remember that the CS+ may indicate danger, but
it also learns that this association is currently not applica-
ble [22]. According to this theory, during fear acquisition
the agent learns that there exists a 'latent cause' that gener-
ates a US contingent on CS+ presentation. During extinc-
tion, they learn that this 'latent cause' is currently absent
– but that it may still exist somewhere. Such a model is
supported by recent studies of neural ensemble coding dur-
ing the formation and extinction of rodent fear memories
in which extinction does not return the relevant neural pop-
ulations to the default state [23]. In novel spatiotemporal
environments (recovery/renewal), or in contexts where the
threat was recently encountered (reinstatement), the agent
will infer that the initial cause of the US is likely to be pre-
sent again, and thus respond to the CS+. This is why it ap-
pears to be very difficult to entirely “erase” a fear memory
with behavioural (non-pharmacological) procedures once
it has been acquired [21], although it may not be impos-
sible [24]. More recent work has therefore looked into the
possibility of pharmacologically altering fear memory.
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Importantly, cued Pavlovian fear conditioning is only one
model of aversive memory, and mainly based on synaptic
plasticity in basolateral and central amygdala. Other, close-
ly related memory models, such as contextual conditioning
or trace fear conditioning (where the predictor and out-
come are separated by a temporal gap), require synaptic
plasticity in macroscopically distinct brain structures such
as the hippocampus [25, 26], and fear extinction crucially
relies on prefrontal cortex plasticity [20]. Close scrutiny is
therefore required to determine whether results from fear
conditioning paradigms can be extrapolated to other exper-
imental paradigms or to clinical application.
Memory reconsolidation blockade to erase fear
memory
After a memory is consolidated in a protein synthesis-de-
pendent process, retrieval of that memory renders it la-
bile [20]. Under physiological conditions, a subsequent
spontaneous reconsolidation process stabilises the memo-
ry. Chemically blocking this process erases fear memories
in rodents [27]. In this reconsolidation blockade paradigm,
an animal is exposed to a CS+/US coupling on day one.
After this memory is consolidated on day two, the memo-
ry is re-activated by the presentation of just one CS+. Im-
mediately afterwards, the protein synthesis inhibitor ani-
somycin is injected into the amygdala, the structure in
which synaptic re-modelling to store the CS+/US associ-
ation occurs [20]. On day three, the animal is exposed to
the CS+ again. Unlike on day one, the animal shows no
conditioned freezing response to the CS+. However, if ani-
somycin is injected six hours after re-activation rather than
immediately after it, the fear memory is left intact [27].
Cued fear memory can be erased not only on the day after
training, but also two weeks later [27]. Although contextu-
al memories appear to become more stable after systems-
level consolidation, they can still be erased after more than
five weeks [28], and a clear temporal boundary when they
become inerasable has not yet been found [29]. Reconsoli-
dation appears to truly erase fear memories, i.e. they don't
re-appear after reinstatement or recovery [30]. A pre-con-
dition for retrieval to make a memory labile appears to be
that the retrieval experience is not entirely predictable [31].
In the initial study by Nader et al., for example, the CS+
was not followed by the US, and this omission of the US
constituted an unexpected event.
The precise boundary conditions for reconsolidation
blockade are still unknown [29]. Nevertheless, the proce-
dure provides a potential way of modifying memory by re-
activating a particular memory and then interfering with its
reconsolidation. Anisomycin is toxic for humans, but other
interventions have been repeatedly demonstrated to block
reconsolidation in rodents as well: electroconvulsive shock
[32], amnesic agents such as benzodiazepines [33] and the
noradrenalin antagonist propranolol [34]. In humans, elec-
troconvulsive shock [35] and propranolol [36–38] have
been shown to impair reconsolidation. Purely behavioural
manipulations (stress, information interference, retrieval-
extinction) have also been suggested as ways to disrupt re-
consolidation, but were harder to replicate across studies
[39, 40].
Interestingly, post-retrieval propranolol appeared to block
the memory for involuntary conditioned responses to the
CS+, but not the declarative recollection of CS+/US asso-
ciations [36]. Several studies have demonstrated the poten-
tial of the reconsolidation blockade approach for transla-
tional neuroscience and its potential clinical relevance [39,
41]. Since ECM components play a role in the synaptic
remodelling that underlies memory formation and mainte-
nance, this encourages investigations into their contribu-
tion to synaptic plasticity during reconsolidation.
MMPs and learning
MMPs are a group of enzymes (23 in humans) that are in-
volved in the structural remodelling of the ECM inside and
outside the brain [4]. The most widely researched MMP
is arguably MMP-9, for which marker reagents exist [4].
MMPs’ contribution to structural ECM pathology outside
the brain has long been recognised, and MMP inhibitors
are clinically tested or approved to treat conditions such
as breast cancer [42], corneal erosion [43], rosacea [44]
and periodontitis [44]. Similarly, MMPs are involved in
the pathological proteolysis which occurs in brain patholo-
gies such as hypoxia and ischaemia, traumatic injury and
neuroinflammation [4]. More recently, it has emerged that
MMPs are also involved in an extracellular signalling path-
way that drives learning on a short timescale of about 30
minutes (figure 1). The level of activity of several MMPs
is increased in behavioural tasks involving learning and
memory [45, 46]. More specifically, the electrophysiolog-
ical phenomenon of long-term potentiation (LTP) is based
on structural synaptic changes that causally underlie learn-
ing and memory [6, 47]. MMP-9 is a critical component
in the signalling pathway that leads to some forms of LTP,
such as late-phase LTP. Pharmacological MMP-9 inhibi-
tion, applying an endogenous tissue inhibitor of metallo-
proteinases (TIMP), or genetic knock-out of MMP-9 re-
duces LTP [48–52]. MMP-9 is transported to synapses at
times of neural activity [53], and co-localises with the NM-
DA- and AMPA-receptors involved in LTP [54]. Crucial-
ly, when MMP-9, which is typically released as an inac-
tive preform, is activated and applied to the synapse, it
chemically induces LTP [48, 50]. This supports the view
that MMP-9 has an instructive role in a signalling pathway
leading to LTP, although this role appears to vary depend-
ing on the pathways and receptor types involved [55]. Be-
yond LTP, synaptic structure changes induced by MMP-9
have been demonstrated [50]. As a possible pathway, it has
been suggested that stimulation of the serotonin receptor
5-HT7R activates MMP-9, which cleaves the transmem-
brane protein CD44, a receptor for the ECM component
hyaluron, and that this pathway, also involving the GTPase
Cdc42, contributes to dendritic spine remodelling and LTP
[56]. The extent to which other known proteolytic targets
(e.g. growth factors and their precursors, cell surface re-
ceptors, several cell adhesion molecules) or non-proteolyt-
ic binding targets of MMP-9 contribute to this pathway re-
mains unknown [57].
While the aforementioned studies were conducted in slice
preparations, there is also in vivo evidence for MMP-9’s
involvement in learning and memory. In rodents, MMP in-
hibition reduces spatial and contextual learning [58, 59].
Regarding Pavlovian fear conditioning, one rodent study
suggested that MMP-9 inhibition does not impair one-
trial learning – a specific form of fear conditioning – but
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Figure 1: ECM and synaptic plasticity regulation. Different mechanisms underlying the impact of ECM components on synaptic plasticity
are suggested.
does inhibit the reconsolidation of fear memories acquired
through a more standard protocol with four learning trials
[60]. In humans, it has been shown that the broad spectrum
MMP inhibitor doxycycline reduces Pavlovian fear acqui-
sition/consolidation [61]. Since doxycycline is a clinically
approved and relatively safe drug, it may provide a use-
ful mechanism of action for the translational application of
MMP-9 interference. Other forms of fear conditioning that
require plasticity outside the amygdala are yet to be inves-
tigated. For example, hippocampal synaptic plasticity is re-
quired for trace conditioning (where the CS+ and US are
separated by a time interval) [25] and context conditioning
(where a spatial context predicts the US) [26].
PNNs and learning
PNNs are a particular ECM structure that is only found in
the brain, and only around certain neurons and in certain
brain regions. They were characterised by Golgi in 1898,
but remained a specialist topic until the late 20th century
[62]. PNN development is terminated during adolescence
[63]. A wealth of research has demonstrated that PNN mat-
uration ends critical periods in the visual system. For ex-
ample, monocular deprivation in young animals impedes
the development of vision in the deprived eye [64]. In
adults, monocular deprivation has no such impact. The
critical period for this impairment ends when PNNs be-
come fully organised in the visual cortex, and chemical
degradation of PNNs reinstates the critical period: monoc-
ular deprivation will then reduce vision for the deprived
eye [65]. The deposition of PNNs appears to be related to
neural activity [66]. Thus, the role of PNNs is often de-
scribed as limiting neural plasticity after critical periods
during adolescence [63]. This has driven exploration of the
role of PNNs in other learning processes.
Indeed, a similar critical period is observed for Pavlovian
fear conditioning. Adult rats (i.e. on postnatal day 23) pass
tests for the stability of fear memory after extinction train-
ing. Younger rats, however, (i.e. postnatal day 16 days)
appear to completely forget ('erase') fear memory during
extinction, rather than establish competing memories
[67–69]. This critical period is limited by the maturation
of PNNs in basolateral amygdala, where synaptic plasticity
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is required for fear conditioning [5]. When adult PNNs in
amygdala are chemically degraded before fear condition-
ing, the ensuing fear memories can be fully erased by ex-
tinction training [5]. Similarly, the auditory cortex is rel-
evant for some forms of auditory learning, and degrading
PNNs increases flexibility for re-learning [70]. On the oth-
er hand, PNNs may also be required for the initial learn-
ing process (which was unimpaired in the aforementioned
studies). For example, fear memory with a simple auditory
CS+ does not initially require the auditory cortex, but its
consolidation takes place in the auditory cortex. Degrad-
ing auditory cortex PNNs appears to either block consoli-
dation, or to make consolidated fear memory malleable for
erasure [71]. All of these data suggest that PNNs play a
profound role in memory formation and maintenance.
It is not yet known whether this role is permissive, i.e. en-
abling or protecting memory formation that takes place via
other mechanisms, or instructive, i.e. providing the actual
surrogate for memory [72]. PNN structures are predomi-
nantly observed around parvalbumin-expressing GABAer-
gic interneurons [73], and GABAergic inhibitory transmis-
sion is fundamental in controlling neuronal excitability,
dendritic integration and spike-timing, as well as neuronal
synchronisation and the generation of oscillations. PNNs
reduce GABAergic inhibition by acting as a physical bar-
rier, limiting neurotransmitter diffusion. The identification
of neuronal activity-dependent remodelling and/or degra-
dation of PNNs and other ECM components has fostered
several bold hypotheses regarding their function (figure 1)
[74]. By compartmentalising the perisynaptic space, PNNs
sequestrate neurotrophins and transcription factors and
control ligand–cell surface receptor interactions [75]. As a
diffusion barrier, the ECM/PNN affects the diffusion of re-
ceptors laterally within the plasma membrane and at the
synaptic cleft, linking it to a particular form of plastic-
ity known as synaptic scaling [76]. Synaptic scaling al-
lows neurons to compensate for prolonged changes in fir-
ing rates by adjusting their synaptic strength. It is crucial
for maintaining network stability. At glutamatergic synaps-
es, the PNN protein NARP mediates scaling in an activity-
dependent manner by clustering AMPA receptor subunits,
while reelin signalling alters the lateral diffusion of NM-
DA receptors [77, 78]. Lateral diffusion of GABA-A re-
ceptors also contributes to synaptic scaling [79]. The
mechanism underlying the ECM/PNN-dependent regula-
tion of GABAergic synaptic strength is largely unknown.
Interestingly, other ECM structures and enzymes have also
been implicated in synaptic plasticity regulation [80, 81].
PNNs and MMPs across different timescales
Synaptic plasticity regulation by both PNNs and MMPs
occurs over various timescales. We discussed how MMPs
are part of a signalling pathway that induces LTP in exci-
tatory synapses on short timescales of 30-60 minutes. On
the other hand, PNNs, which mainly surround inhibitory
synapses (pyramidal neurons in hippocampal area CA2 ap-
pear to be an exception to this rule [82]), permanently in-
hibit synaptic plasticity. MMPs are involved in, and pos-
sibly required for, the degradation of the molecules that
make up PNNs [83]. Many memories undergo systems-
level consolidation on timescales of hours. This is accom-
panied by the electrophysiological phenomenon of sharp-
wave ripple (SWR) events in the hippocampus [84].
Degradation of PNNs reduces the occurrence of this phe-
nomenon [85], and thus PNNs also contribute to systems-
level consolidation. Finally, on a timescale of a day, SWRs
are intimately associated with sleep, which itself strongly
facilitates memory consolidation. The processes involved
here are likely twofold: the reinforcement of some synaps-
es and the weakening of others [86]. It is possible that
SWRs play a role in both processes [87, 88] through mech-
anisms that are not yet well understood. Roles for MMPs
and PNNs here seem promising, but are unexplored. This
long-term temporal regulation is preserved even on a cellu-
lar level: hippocampal LTP is regulated in circadian fash-
ion both in vitro and in vivo, likely regulated by circadian
MAPK signalling [89]. In turn, though the daily regulation
of PNNs and neuronal MMPs is unknown, the regulation
of MMPs by MAPK pathways during astrogliosis is well-
documented [90].
ECM alterations in psychiatric disorders
Post-mortem studies have revealed that PNNs decrease
in several brain areas in schizophrenia [91–93] and to a
lesser extent in bipolar disorder [92]. PNN integrity may
also be involved in the pathogenesis of depression [94,
95]. The expression of several ECM molecules, including
chondroitin sulfate proteoglycans [92, 93] and reelin [96],
is also decreased in schizophrenia. In a genome-wide asso-
ciation study, a genetic polymorphism in a region coding
for the ECM enzyme MMP-16 was associated with schiz-
ophrenia [97]. Phenotype-based genetic association studies
found a relationship between the early onset of schizophre-
nia and a polymorphism in the region coding for the cell
adhesion molecule contactin-4, and also a relationship be-
tween the severity of chronic delusions and a polymor-
phism in a non-coding region related to the MMP-9 gene
[98]. The latter polymorphism appears to relate to MMP-9
expression and dendritic spine morphology in vitro, and to
phenotypic changes in mice [98].
Post-mortem studies have also suggested that reelin ex-
pression is reduced in autism [99]. Other disorders where
MMP has been implicated in one way or another include
addiction [100], as well as affective disorders and fragile
X syndrome, for which MMP-inhibitors are being evaluat-
ed as a treatment (see [57, 94] for review). Since Fragile
X syndrome is linked to sleep and circadian disturbances
[101, 102], there is also the possibility that MMPs might
play similar roles, though this has not been investigated.
ECM alterations could contribute to pathology in many
different ways, ranging from developmental changes af-
fecting cell migration and axonal guidance to the ECM's
permissive role in providing a suitable environment for
neuronal function, and to more specific influences on
synaptic plasticity [63]. An influential theory has suggest-
ed that reduced PNN integrity in schizophrenia may in-
crease the vulnerability of parvalbumin-positive interneu-
rons to oxidative stress, which would reciprocally degrade
PNNs further [103].
Discussion
We have reviewed the literature on ECM contributions to
learning and memory, and how this could be leveraged to
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understand the experience dependence of psychiatric con-
ditions or contribute to learning-based treatments. A nov-
el avenue for the treatment of pathological memories is re-
consolidation blockade, which has – in different forms and
with mixed success [39] – already been translated into clin-
ical pilot trials. We suggest that ECM contributions to plas-
ticity provide a mechanism by which to impact on memory
consolidation and reconsolidation. Future work will focus
on understanding the underlying pathways, their potential
influence upon pathology, and their clinical translation to
advance psychiatric treatment. Researchers have called for
the increased integration of basic science findings in order
to better understand treatment mechanisms and to increase
the effectiveness of evidence-based treatments for psychi-
atric disorders [104]. Significant strides have been made
in developing and refining psychotherapeutic treatments,
which are recommended as first-line treatments for many
psychiatric disorders, including anxiety and PTSD. How-
ever, there is significant room to improve these treatments,
and they may benefit from innovations such as ECM mod-
ification.
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